KLF16 and bladder transitional cell carcinoma: Targeting this loop with bromodomain and extraterminal (BET) inhibitors, by impairing the transcription of KLF16 and MYC, leads to reduced cell viability, tumor growth, and increased sensitivity to chemotherapy in BLCA.